Cardiomyocytes Market - Top Companies and Manufacturers

  • Report ID: 5972
  • Published Date: Apr 03, 2024
  • Report Format: PDF, PPT

Top Featured Companies Dominating the Cardiomyocytes Landscape

    • AstraZeneca
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Novartis
    • Pfizer
    • Roche
    • Johnson & Johnson
    • Merck & Co., Inc.
    • Bayer
    • Abbott Laboratories
    • Bristol Myres
    • Cytiva

Browse Key Market Insights with Data Illustration:

In the News

  • 31st January 2024

Abbott Park, Illinois /PRNewswire/ -- The world leader in science-based nutrition, Abbott (NYSE: ABT), has announced the introduction of its new PROTALITYTM brand. The first product in this range to cater to the increasing number of adults who want to lose weight without sacrificing healthy nutrition and muscle mass is the high-protein nutrition smoothie.

  • 6th December 2023

Novartis announced that Fabhalta® (iptacopan) has been approved by the U.S. Food and Drug Administration (FDA) as the first oral monotherapy for the management of adults suffering from paroxysmal nocturnal hemoglobinuria (PNH)1. A Factor B inhibitor, fabhalta functions proximally in the immune system's alternative complement pathway, offering complete regulation of the destruction of red blood cells (RBCs) both inside and outside of blood vessels (intra- and extravascular hemolysis [IVH and EVH]).

Author Credits:  Radhika Gupta, Shivam Bhutani

  • Report ID: 5972
  • Published Date: Apr 03, 2024
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

The major factors driving the growth of the Cardiomyocytes market are the rising incidence of cardiovascular diseases in the world, rising investments in research and development, expanding adoption of cell therapy, and increase in healthcare expenditure and reimbursement policies.

The market size of cardiomyocytes is anticipated to attain a CAGR of 10% over the forecast period, i.e., 2024-2036.

The major players in the market are AstraZeneca, Novartis, Pfizer, Roche, Johnson & Johnson, Merck & Co., Inc., Bayer, Abbott Laboratories, Bristol Myres, Cytiva, and others.

The Human iPSC-derived Cardiomyocytes segment is anticipated to garner the largest market size by the end of 2036 and display significant growth opportunities.

The market in the North America region is projected to hold the largest market share by the end of 2036 and provide more business opportunities in the future.
Inquiry Before Buying Request Free Sample

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying